Shares of BioSpecifics Technologies Corp. (NASDAQ:BSTC) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Analysts have set a 1 year consensus price target of $81.00 for the company and are expecting that the company will post $0.68 earnings per share for the current quarter, according to Zacks. Zacks has also given BioSpecifics Technologies an industry rank of 81 out of 255 based on the ratings given to related companies.
Several equities research analysts have commented on BSTC shares. Zacks Investment Research downgraded BioSpecifics Technologies from a “buy” rating to a “hold” rating in a report on Monday, February 4th. HC Wainwright reissued a “buy” rating and set a $81.00 price target on shares of BioSpecifics Technologies in a research note on Friday, January 25th. Finally, BidaskClub lowered BioSpecifics Technologies from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 24th.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC lifted its stake in BioSpecifics Technologies by 2.5% during the fourth quarter. Squarepoint Ops LLC now owns 7,950 shares of the biopharmaceutical company’s stock valued at $482,000 after purchasing an additional 192 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of BioSpecifics Technologies by 50.1% during the 4th quarter. Legal & General Group Plc now owns 1,211 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 404 shares during the period. Great West Life Assurance Co. Can acquired a new stake in shares of BioSpecifics Technologies during the 4th quarter worth about $54,000. Meeder Asset Management Inc. increased its position in BioSpecifics Technologies by 82.0% in the 3rd quarter. Meeder Asset Management Inc. now owns 2,344 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 1,056 shares in the last quarter. Finally, California Public Employees Retirement System grew its position in shares of BioSpecifics Technologies by 8.2% during the 2nd quarter. California Public Employees Retirement System now owns 18,153 shares of the biopharmaceutical company’s stock worth $814,000 after buying an additional 1,382 shares during the period. 58.56% of the stock is owned by institutional investors.
Shares of BSTC traded down $1.40 during trading hours on Wednesday, reaching $70.10. 33,500 shares of the company’s stock traded hands, compared to its average volume of 47,735. The company has a market cap of $521.26 million, a PE ratio of 41.24 and a beta of 1.27. BioSpecifics Technologies has a 12 month low of $38.05 and a 12 month high of $73.31.
BioSpecifics Technologies Company Profile
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brand names.
Recommended Story: Growth Stocks, What They Are, What They Are Not
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.